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Osteosarcoma, the most common malignant bone tumor of childhood, is a high-grade pri-
mary bone sarcoma that occurs mostly in adolescence. Standard treatment consists of
surgery in combination with multi-agent chemotherapy regimens. The development and
approval of imatinib for Philadelphia chromosome-positive acute lymphoblastic leukemia
in children and the fully human monoclonal antibody, anti-GD2, as part of an immune
therapy for high-risk neuroblastoma patients have established the precedent for use of
targeted inhibitors along with standard chemotherapy backbones. However, few targeted
agents tested have achieved traditional clinical endpoints for osteosarcoma. Many biologi-
cal agents demonstrating anti-tumor responses in preclinical and early-phase clinical testing
have failed to reach response thresholds to justify randomized trials with large numbers
of patients. The development of targeted therapies for pediatric cancer remains a signif-
icant challenge. To aid in the prioritization of new agents for clinical testing, the Pediatric
Preclinical Testing Program (PPTP) has developed reliable and robust preclinical pediatric
cancer models to rapidly screen agents for activity in multiple childhood cancers and estab-
lish pharmacological parameters and effective drug concentrations for clinical trials. In this
article, we examine a range of standard and novel agents that have been evaluated by the
PPTP, and we discuss the preclinical and clinical development of these for the treatment
of osteosarcoma.We further demonstrate that committed resources for hypothesis-driven
drug discovery and development are needed to yield clinical successes in the search for
new therapies for this pediatric disease.
Keywords: pediatric preclinical testing program, osteosarcoma, event-free survival, complete response, maintained
complete response, partial response, progressive disease with growth delay, progressive disease
INTRODUCTION
Osteosarcoma (OS), Ewing sarcoma, and rhabdomyosarcoma, are
the most common sarcomas in children and adolescents. OS
is the most frequent bone cancer occurring mostly in children
and adolescents between 10 and 20 years of age (Vander Griend,
1996). It is thought to arise from mesenchymal bone forming tis-
sue and its histological hallmark is the production of malignant
osteoid (Mohseny et al., 2009). The metaphyseal growth regions
of the long bones of the extremities are the most common site
of the primary bone tumor with peak incidences following the
adolescent growth spurt and the seventh and eighth decades of
life (Marina et al., 2004). Current multimodal therapy consist-
ing of surgery and chemotherapy, achieves a 5-year survival rate
of approximately 60–70% in children while patients who present
with metastatic disease at diagnosis have a 10–30% survival rate
(Ferrari and Palmerini, 2007). The chemotherapy agents which
have long demonstrated anti-tumor activity in OS include cis-
platin, doxorubicin, ifosfamide, and high dose-methotrexate (Jaffe
et al., 1995; Ferrari and Palmerini, 2007). The use of novel effective
therapeutic approaches and treatment strategies in patients who
are resistant to current therapy could provide an improvement in
outcome in patients.
Attempts to identify “druggable” targets in OS tumors have
demonstrated a complex karyotype and multiple interacting pro-
teins and pathways implicated in the development of OS. Aneu-
ploidy and inconsistent genetic aberrations have been described in
OS (Mohseny et al., 2009), but no single targetable genetic event
appears to define this disease. It has been shown that the tumor
suppressor p53 is commonly mutated in sporadic OS (Miller et al.,
1990). Mutated or deleted p53 alters cellular resistance to DNA
damage that can affect the cells capacity to evade the toxic effects
of DNA damaging agents. Alterations in genes that regulate p53
including the murine double minute 2 (MDM2), cyclin depen-
dant kinase 4 (CDK4) (Mejia-Guerrero et al., 2010), and the p14
product of the INK4A gene (Benassi et al., 2001) have also been
identified in OS. Several groups have demonstrated that muta-
tions in the retinoblastoma (Rb1) gene located on chromosome
13 occurred in a high percentage of OS samples (Wong et al.,
1997; Nielsen et al., 1998). High frequencies of allelic loss have
been detected at 3q and 18q (Yamaguchi et al., 1992), suggest-
ing that other tumor suppressor genes may be important in OS.
In one study conducted by Ebb et al. (2012) overexpression of
human epidermal growth factor receptor 2 (HER2/neu, ErbB2)
was suggested to be associated with early pulmonary metastases
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and decreased survival in approximately 40% of cases. Expres-
sion of bone morphogenetic protein type II receptor (BMPR2)
was also found to correlate with metastasis (Guo et al., 1999).
Patients with Rothmund–Thomson Syndrome, associated with a
high incidence of OS, have mutations in the RecQ protein-like
4 (RECQL4) gene (Simon et al., 2010). In addition, tumors have
multiple alterations in gene expression affecting surface receptors,
self renewal pathways, angiogenesis, and mechanisms of resistance.
OS tumors do not appear “addicted” to specific and identifi-
able mutations or aberrant pathways, thus presenting a significant
challenge in defining potential strategies for the development of
targeted therapy.
It is becoming increasingly apparent that few novel targeted
agents are capable of achieving single-agent clinical responses
despite proof of target inhibition, to justify advancement in clin-
ical development. Understanding the relevant molecular targets,
as well as the mechanisms by which sarcomas are able to escape
targeted therapies, are critical steps in defining effective clinical
applications for new compounds. The establishment of robust pre-
clinical models may be an effective tool to aid in the prioritization
of the most effective molecularly targeted therapies. The Pediatric
Preclinical Testing Program (PPTP) is an initiative supported by
the National Cancer Institute (NCI) made up of a consortium of
institutions in the United States and Australia (Houghton et al.,
2007). The PPTP has established various models of childhood
cancers using panels of xenograft tumors and cell lines for eval-
uation of in vivo and in vitro anti-tumor activity of standard
and novel agents. Tumor lines include rhabdoid, Wilms tumor
and Ewing sarcoma, rhabdomyosarcoma, neuroblastoma, medul-
loblastoma, ependymoma, glioblastoma, OS, B-cell precursor, and
T-acute lymphoblastic leukemia (ALL). Response criteria for the
solid tumor panels are categorized as high, intermediate, or low.
Agents inducing objective responses [partial response (PR), com-
plete response (CR), or maintained complete response (MCR)]
are considered highly active against the tumor xenograft. A PR
is defined as ≥50% tumor volume regression, CR is immeasur-
able tumor volume and MCR is maintained CR at the end of the
experimental study (Houghton et al., 2007). Agents inducing stable
disease (less than 50% reduction in tumor volume and less than a
25% increase in tumor volume) or progressive disease with tumor
growth delay (PD2) are considered to have intermediate activi-
ties. Agents producing progressive disease without tumor growth
delay (PD1) are considered to have a low level of activity against
the tested xenograft (Houghton et al., 2007). These response and
activity definitions will be used throughout this review.
Improvements in outcome in pediatric OS have been achieved
without the addition of novel agents, but rather through opti-
mization of the dose, combination, schedule, and duration of
treatment using standard systemic chemotherapy. Over the last
decade, technological advances in research and medicine have
provided detailed descriptions of factors that contribute to the
malignant phenotype of this disease with the hope of finding
new therapeutic treatments and strategies. The recent review of
van Maldegem et al. (2012) of published clinical trials for OS
shows that most phase III trials are combination treatments of
conventional chemotherapy agents. Many biological based treat-
ments evaluated in the PPTP and phase I and II trials have yet
to advance to phase III trials. This review summarizes the results
of preclinical testing of agents in OS models conducted by the
PPTP over the past 6 years (Tables 1 and 2). In particular, we have
focused on agents that have demonstrated high and intermediate
activities in preclinical OS models and we highlight the outcome
of early-phase trials for these targeted therapies. The review dis-
cusses trials listed in clinicaltrials.gov and published in PubMed
that are informative about the development of novel therapies.
Clinical trials were selected if they were specific for pediatric OS
or if they enrolled children with OS. Our aim will be to discuss the
available clinical data concerning the efficacy and safety of novel
agents in pediatric OS, with a focus on those agents evaluated by
the PPTP.
AGENTS WITH ACTIVITY IN THE PPTP OSTEOSARCOMA
PANELS
MULTI-TYROSINE KINASE INHIBITORS
Tyrosine kinases are divided into two main classes, receptor tyro-
sine kinases (RTKs) and non-RTKs that lack transmembrane
domains and are found in the cytosol, nucleus, and inner sur-
face of the plasma membrane (Casaletto and McClatchey, 2012).
Tyrosine kinases regulate cellular proliferation, survival, differen-
tiation, function, and motility. Preclinical studies suggest the use of
multi-RTKs in OS may be a powerful tool in these tumors which
show overexpression of several RTKs including ErbB2, IGF-1R,
PDGFR, VEGFR, and activated downstream signal-transduction
pathways, as potential targets (Rettew et al., 2012). The proto-
typical tyrosine kinase inhibitor imatinib, which has dramati-
cally changed the management and improved the prognosis of
patients with Philadelphia chromosome-positive chronic myel-
ogenous leukemia (CML) and ALL and has shown efficacy in some
solid tumors, including gastrointestinal stromal tumor (GIST) and
dermatofibrosarcoma protuberans (DFSP) has demonstrated little
evidence of efficacy in OS (Bond et al., 2008). A number of other
small-molecule tyrosine kinase inhibitors have been preclinically
and clinically evaluated for this disease.
Src inhibitor
Src is a non-RTK involved in pathways regulating cell growth,
survival, and migration (Creedon and Brunton, 2012). Src is
overexpressed in OS and mediates PI3K/Akt anoikis resistance
(Diaz-Montero et al., 2006). In OS, inhibition of c-Src prevents
cell invasion and induces apoptosis in vitro and reduces tumor
growth in vivo (Akiyama et al., 2008). Dasatinib, a multi-tyrosine
kinase small-molecule inhibitor against Src family kinases, which
is also approved for first and second line therapy of CML and
Philadelphia chromosome-positive ALL (Steinberg, 2007; Aguilera
and Tsimberidou, 2009) was tested against the PPTP OS xenograft
panels.
These studies by the PPTP demonstrated that dasatinib had
intermediate activity in two of six OS xenograft lines (Kolb et al.,
2008a) to indicate efficacy in OS. In an in vivo model of metastasis,
Hingorani et al. (2009) showed effective target inhibition in pri-
mary tumors by dasatinib, with no effect on pulmonary metastasis
suggesting that the development of pulmonary metastases in OS
is independent of Src activation. Lung metastasis is usually associ-
ated with poor prognosis in OS patients and these findings along
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Table 1 | Agents tested by the PPTP with high (H) and intermediate (I) activities in osteosarcoma xenografts and corresponding clinical trials
that include pediatric patients with osteosarcoma.
Target Agent Reference Response
activity
Clinicaltrial.gov identifier
Multiple-tyrosine kinases Dasatinib Kolb et al. (2008a) I NCT00464620, NCT00788125
VEGFR Cediranib (AZD 2171) Maris et al. (2008a) I NCT00321581
VEGFR Sorafenib Keir et al. (2010) I NCT00665990, NCT01518413
VEGFR Sunitinib Maris et al. (2008b) I –
IGF-1R SCH 717454 Kolb et al. (2008b) I NCT00617890, NCT00960063
IGF-1R IMC-A12 (Cixutumumab) Houghton et al. (2010a) I NCT00609141, NCT00880282,
NCT00831844
IGF-1R BMS-754807 Kolb et al. (2011) I –
mTOR Rapamycin Houghton et al. (2008a,
2010b)
H –
mTOR AZD8055 Houghton et al. (2012a) I –
Aurora kinase A MLN8237 (Alisertib) Maris et al. (2010) H NCT00739427, NCT01154816
Akt/protein kinase B MK-2206 Gorlick et al. (2012a) I
Akt/protein kinase B GSK690693 Carol et al. (2010b) I –
MEK1/2 AZD6244 Kolb et al. (2010) I –
CDK SCH 727965 (Dinaciclib) Gorlick et al. (2012b) I –
p53 JNJ-26854165 (Serdemetan) Smith et al. (2012a) H –
CENP-E GSK923295A Kolb et al. (2008a), Lock et al.
(2012)
H –
HDAC Vorinostat (SAHA) Keshelava et al. (2009) I NCT00217412, NCT01132911, NCT01422499,
NCT01294670
SMAC LCL161 Houghton et al. (2012b) I –
Mitotic spindle Eribulin Kolb et al. (2013) H
Topoisomerase I Topotecan Carol et al. (2010a) H NCT01670175
Topoisomerase I Genz-644282 Houghton et al. (2012c) H –
I, intermediate activity; H, high activity.
Table 2 | Agents tested by the PPTP with low activity (L) in osteosarcoma xenografts and corresponding clinical trials that include pediatric
patients with osteosarcoma.
Target Agent Reference Response
activity
Clinicaltrial.gov identifier
Bcl-2/Bcl-XL ABT-263 Lock et al. (2008) L –
EGFR Lapatinib Gorlick et al. (2009) L NCT01454804
HSP90 AT13387 Kang et al. (2012) L –
HSP90 Alvespimycin Smith et al. (2008) L –
Immune system Lenalidomide Reynolds et al. (2011) L –
MDM2 RG7112 Carol et al. (2013) L –
NEDD8-activating enzyme MLN4924 Smith et al. (2012b) L –
PIMI kinase SGI-1776 Batra et al. (2012) L –
Proteosome Bortezomib Houghton et al. (2008b) L NCT00994500
y-Secretase RO4929097 Kolb et al. (2012a) L –
Unknown Seneca valley virus Morton et al. (2010) L –
L, low activity.
with reports of differences in gene expression patterns between the
primary tumor and lung metastasis (Namlos et al., 2012) could
aid the development of targeted therapy strategies. Single-agent
testing of dasatinib in pediatric patients with OS showed subopti-
mal responses. In the phase I COG trial, none of the five patients
experienced disease stabilization beyond the first course of therapy
(Aplenc et al., 2012). The Sarcoma Alliance for Research through
Collaboration (SARC) is conducting a phase II study of dasatinib
for advanced sarcoma patients 13 years and older (NCT00464620),
but this study is not inclusive of patients with OS. Dasatinib
www.frontiersin.org May 2013 | Volume 3 | Article 132 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sampson et al. Targeted therapies for osteosarcoma
is also being investigated in combination with chemotherapy.
Ongoing trials include the phase I/II study (NCT00788125) of
dasatinib in combination with ifosfamide, carboplatin, and etopo-
side in young patients with metastatic or recurrent malignant solid
tumors, including OS (Table 1). Of note, a SARC randomized trial
of another Src inhibitor saracatinib (AZD0530) in patients with
recurrent OS localized to the lung is ongoing (NCT00752206).
Vascular endothelial growth factor receptor inhibitors
The vascular endothelial growth factor (VEGF) pathway is
involved in angiogenesis and is crucial for tumor growth and pro-
gression. Several agents for anti-angiogenic therapies have been
developed that target either VEGF or its cell surface receptors
to induce anti-proliferative, anti-angiogenic, and proapoptotic
effects. Of the three VEGF receptor isoforms (VEGFR-1, -2, and
-3), VEGFR-3 is overexpressed in OS cell lines and correlates with
poor survival (Lugowska et al., 2011). The PPTP has tested several
tyrosine kinase inhibitors, three of which show potent and relative
selectivity for the VEGF receptor family. These are cediranib (AZD
2171), sorafenib, and sunitinib. Cediranib is an oral bioavailable
small-molecule inhibitor. Sorafenib and sunitinib are two broad
range kinase inhibitors with similar drug profiles and overlapping
targets (PDGFR, FLT3, RET, and KIT) and high selectivity for the
VEGFR family. Both drugs are approved by the FDA for treat-
ment of advanced renal cell carcinoma (RCC). Sorafenib is also
approved for unresectable hepatocellular carcinoma (HCC) (Keat-
ing and Santoro, 2009) and sunitinib is approved for GIST after
disease progression or intolerance to imatinib mesylate (Deeks and
Keating, 2006).
Cediranib was highly effective in the PPTP OS models with
tumor growth delay in four of five xenografts (Maris et al., 2008a).
Objective responses (both CR) were achieved in one OS and
one rhabdoid xenograft. Combination testing of cediranib with
chemotherapy in other xenograft models did not demonstrate
additive benefits (Morton et al., 2012), but this approach was not
tested for OS. Cediranib was evaluated in combination with the
EGFR inhibitor gefitinib in a phase I trial in patients with advanced
solid tumors (van Cruijsen et al., 2010) and demonstrated favor-
able response in one OS patient (PR). In a phase 1 trial and
pharmacokinetic study of cediranib in children and adolescents
with refractory solid tumors (NCT00321581), objective responses
were observed in patients with Ewing sarcoma, synovial sarcoma,
and OS (Fox et al., 2010). Notably, bevacizumab, a humanized
monoclonal antibody (mAb) targeting the VEGF receptor, has
been evaluated in a phase I study in pediatric patients with refrac-
tory solid tumors (Glade Bender et al., 2008) and is currently being
evaluated in combination with chemotherapy (NCT00458731).
The PPTP testing of sorafenib showed significant tumor growth
delay for the OS models (PD2 for five of six tumors) (Keir et al.,
2010). A COG phase I study of sorafenib (Widemann et al., 2012)
was successfully completed and a phase II trial is in progress. In a
phase II trial conducted by the Italian sarcoma group in a cohort
of 35 patients greater than 14 years with OS (Grignani et al., 2012),
14% of patients had objective responses (3PR, 2MR) and 29% of
patients had SD. Sorafenib is also being clinically investigated in
combination with bevacizumab (NCT00665990) and irinotecan
(NCT01518413).
Sunitinib demonstrated effective tumor growth inhibition
comparable to sorafenib in the PPTP OS models (PD2 for three of
six tumors) (Maris et al., 2008b). However, the evaluation of suni-
tinib in the COG phase I and pharmacokinetic study in pediatric
patients with refractory solid tumors did not achieve objective
responses. Stable disease was reported for one OS patient in this
study (Dubois et al., 2011, 2012), but concerns for cardiac toxi-
city have limited interest in additional trials. Further preclinical
testing of these VEGF-targeted agents in combination with con-
ventional chemotherapeutic regimens may enhance the efficacy of
these drugs in the treatment of OS tumors.
Insulin-like growth factor-1 receptor inhibitors
The insulin-like growth factor-1 receptor (IGF-1R) is a transmem-
brane RTK for which selective IGF-1R tyrosine kinase inhibitors
have been developed. The binding of insulin-like growth factor-1
and 2 (IGF-1 and IGF-2) to the IGF-1R results in autophospho-
rylation and subsequent activation of multiple signaling pathways
including the Ras/Raf/mitogen-activated protein kinase (MAPK)
and PI3K/Akt pathways which both regulate cell growth and devel-
opment (Tognon and Sorensen, 2012). IGF-1R has been impli-
cated in the development of sarcomas and inhibition of IGF-1R
function has been demonstrated to reduce growth in OS, rhab-
domyosarcoma, and Ewing sarcoma cell lines (Toretsky et al., 1997;
Scotlandi, 2006). More than 25 antibodies and small molecules
that specifically inhibit IGF-1R have undergone preclinical and
clinical testing in both adults and children. Of these, two fully
humanized mAbs SCH 717454 and cixutumumab (IMC-A12)
and one small-molecule ATP-competitive inhibitor of IGF-1R,
BMS-754807 have been evaluated by the PPTP.
In vivo activity of SCH 717454 was demonstrated by tumor
regression (MCR) in two lines and tumor growth inhibition (PD2)
in another two of six OS xenografts (Kolb et al., 2008b). Wang
et al. (2010) also showed similar tumor regression by SCH 717454
in an OS model, with enhanced anti-tumor effects when used in
combination with cyclophosphamide and cisplatin. Preliminary
evidence of anti-tumor activity was reported in a phase II study of
SCH 717454 in subjects with relapsed OS or Ewing sarcoma after
standard therapy (NCT00617890). A planned trial of SCH 717454
in combination with chemotherapy in patients with solid tumors
was recently terminated (NCT00960063).
When evaluated by the PPTP, the mAb cixutumumab demon-
strated single-agent activity in vivo in OS, and induced interme-
diate responses (PD2) in three of five OS xenografts (Houghton
et al., 2010a). Combination (stage 2) testing of cixutumumab with
rapamycin resulted in superior responses compared to the single
agents alone (Kolb et al., 2012b). In a phase II COG trial cixutu-
mumab was also well-tolerated as single-agent therapy in patients
with solid tumors (Malempati et al., 2012). Limited single-agent
activity of cixutumumab was seen mainly in Ewing sarcoma with
a response rate of approximately 10%. The recent study in com-
bination with mammalian target of rapamycin (mTOR) inhibitor
temsirolimus in the relapsed/refractory setting (NCT00880282)
also demonstrated best single-agent activity in Ewing sarcoma
tumors (Naing et al., 2012). In the phase II trial which included
patients with OS, the combination of cixutumumab and tem-
sirolimus showed clinical activity in patients, but did not have
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an effect on median progression-free survival (PFS) (Schwartz
et al., 2013). However, despite clear evidence of clinical benefits
in some pediatric patients, several drug companies have curtailed
or eliminated anti-IGF-1R programs because the observed clin-
ical benefits of targeting this pathway in single and multi-agent
strategies did not met the primary endpoints in many adult tri-
als. The current development of anti-IGF-1R therapy is being
reviewed.
BMS-754807 showed good intermediate response against the
PPTP OS cell lines and induced significant differences in event-
free survival (EFS) in xenografts (PD2 in four of six tumors) (Kolb
et al., 2011). Currently, this compound is not in clinical develop-
ment for pediatric malignancies. These findings highlight current
challenges for future opportunities in anti-IGF-1R developmen-
tal therapies and warrant the investigation of combination and
dosing strategies along with molecular studies of mechanisms of
response to achieve broader activity and greater toxicities with
these therapies.
mTOR INHIBITORS
mTOR is a serine/threonine kinase intermediary within the
PI3K/Akt pathway that regulates protein synthesis, cell prolif-
eration, survival, and angiogenesis. The mTOR complex con-
sists of mTOR complex-1 (mTORC1) which regulates cellular
proliferation and mTOR complex-2 (mTORC2) which phos-
phorylates and activates Akt. Activation of the mTOR path-
way is implicated in the development and progression of OS
(Wan et al., 2005) which makes mTOR an appealing target for
therapeutic intervention. Rapamycin (sirolimus) and rapalogs
(everolimus, temsirolimus, and ridaforolimus) are immunosup-
pressive macrocyclic lactone antibiotics that inhibit the kinase
activity of mTORC1 while mTORC2 is generally rapamycin-
insensitive (Yung, 2010).
Response activity to rapamycin was high in one OS xenograft
(CR) and intermediate in five tumors (PD2) (Houghton et al.,
2008a). Furthermore, the addition of rapamycin to either
cyclophosphamide or vincristine resulted in enhanced responses
in the OS models (Houghton et al., 2010b). A phase II trial
for treatment of advanced sarcoma patients with rapamycin
and cyclophosphamide, did not meet the primary endpoint of
greater than 25% 6-month PFS rate (Schuetze et al., 2012).
Initial reports for everolimus, temsirolimus, and ridaforolimus
(Spunt et al., 2011) have provided evidence of favorable anti-
tumor activity in patients with a broad range of solid tumors.
The randomized phase II trial of ridaforolimus as single-agent
therapy met the primary endpoint of improved PFS in two OS
patients (Chawla et al., 2012). More recently in a phase III sar-
coma maintenance study (Blay et al., 2011), ridaforolimus met
the study endpoint of a statistically significant improvement
in PFS, compared with a placebo group (hazard ratio= 0.72,
P = 0.0001, stratified log-rank) though specific results in OS
are not yet available. Ridaforolimus (an analog of the drug
sirolimus) is under clinical development for numerous adult can-
cers but is not FDA approved. A phase II trial of pazopanib and
everolimus in patients with PI3K mutations and/or phosphatase
and tensin homolog (PTEN) tumor suppressor loss is underway
(NCT01430572).
It is likely that in response to inhibition to mTORC1,
mTORC2 may compensate for loss of mTORC1 activity through
activation of Akt, leading to acquired resistance to rapamycin
and rapalogs (Gulhati et al., 2011). The dual mTOR1/mTOR2
inhibitor AZD8055 demonstrated low activity in vivo against the
PPTP OS xenografts as PD1 was reported for five of six tumors
(Houghton et al., 2012a). AZD8055 is not currently in clinical
development while other novel small-molecule inhibitors that are
mTOR-selective or dual mTOR/PI3K inhibitors have entered clin-
ical trials. A key focus in the development of these drugs will be
to establish the effectiveness of combination strategies with other
targeted therapies and standard cytotoxic agents. IGF-1R signals
through Akt and is suggested to be involved in resistance to mTOR
inhibitors. Combined inhibition of IGF-1R and mTOR has been
evaluated. Antibodies targeting IGF-1R (R1507, figitumumab, cix-
utumumab) in combination with rapamycin and rapalogs showed
enhanced activity compared to the single agents (Juergens et al.,
2011; Quek et al., 2011; Kolb et al., 2012b). The clinical testing
of temsirolimus with cixutumumab in 27 patients demonstrated
prolonged CR in one patient with Ewing sarcoma and PR in four
patients (Naing et al., 2012). The phase I study of everolimus
and CP-751871, a fully human anti-IGF-1R mAb, achieved SD
in patients with sarcoma and other solid tumors (Quek et al.,
2011). Further use of mTOR inhibitors in the treatment of OS
patients is under investigation as single-dose therapy [everolimus
(NCT01216826), sirolimus (NCT01331135)] and multi-agent
therapy [sirolimus and cyclophosphamide (NCT00743509)] with
the major goals of determining effective dosing schedules and
additive combinations.
AURORA A KINASE INHIBITOR
The ability of cancer cells to evade death is one of the hallmarks of
cancer development and loss of cell cycle control leads to dereg-
ulated cell proliferation in many tumors including OS. Aurora
kinases regulate cell cycle transit from G2 through cytokinesis.
Three mammalian aurora kinase genes encode aurora A, B, and
C proteins and inhibition of any of these potentially results in
abnormal mitotic events and apoptosis. Overexpression of aurora
kinases has been correlated with poor prognosis in canine OS,
which his high similarities to the human disease (Mueller et al.,
2007). Currently there are about 30 aurora kinase inhibitors in dif-
ferent stages of preclinical and clinical development (Kollareddy
et al., 2012). MLN8237 (alisertib) was tested by the PPTP (Maris
et al., 2010). Evidence of intermediate to high anti-tumor activity
was demonstrated, as MCR was achieved in one of six OS tumor
xenografts in vivo and intermediate activity was observed for the
other five. This effect was also seen in neuroblastoma tumors
(three of six). A current COG pediatric phase 1/II study investi-
gating MLN8237 in children with relapsed/refractory solid tumors
(NCT00739427) includes a cohort of patients with OS. Dose lim-
iting toxicities of aurora kinase inhibition for neuroblastoma has
been demonstrated (Shang et al., 2009). Of note, in one study,
canine OS cells exhibit resistance to aurora kinase inhibitors (Can-
non et al., 2013). Better biological understanding of tumor specific
variations in drug sensitivity to aurora kinase A inhibitors may also
guide important preclinical evaluation of single and multi-agent
therapies in OS.
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Akt/PKB INHIBITORS
PI3K and Akt activation may drive tumorigenesis in OS by regu-
lating effectors that are different from mTORC1. Inhibition of Akt
signaling is anticipated to reduce tumor survival and enhance the
effectiveness of cytotoxic chemotherapy by increasing apoptosis
(Diaz-Montero et al., 2006; Carol et al., 2010b). The development
of specific inhibitors of Akt is challenging since Akt belongs to the
AGC family of kinases and shares homology with PKA and PKC.
Furthermore, human Akt has three isozymes that show >85%
homology (Akt1, Akt2, and Akt3) but distinct functionality. Speci-
ficity as well as isozyme selectivity of Akt inhibitors will be critical
for optimal anti-apoptotic effects of tumor cells in vivo. MK-2206,
a highly selective non-ATP-competitive allosteric Akt inhibitor and
GSK690693 a novel ATP-competitive, pan-Akt kinase inhibitor
selective for the Akt isoforms were two agents tested for anti-tumor
activity by the PPTP (Carol et al., 2010b; Gorlick et al., 2012a).
MK-2206 showed significant differences in EFS distribution
in vivo against OS xenografts including PD2 in two tumors, but
no objective responses (Gorlick et al., 2012a). Of note, triciribine, a
nucleoside analog that causes dephosphorylation of active Akt was
evaluated for adult OS but showed no responses and unexpected
toxicity (Garrett et al., 2011). One explanation is that activation of
Ras/Raf signaling pathways and the mTOR signaling cascade, may
limit the efficacy of Akt/PKB targeted therapy (Carol et al., 2010b),
and suggests that the feedback phosphorylation of Akt and activa-
tion of the PI3K/Akt pathway may be a mechanism for resistance.
Concomitant disruption of these mechanisms may be an effective
strategy for the development of novel anti-cancer therapies. These
findings reiterate the need for extensive preclinical testing of these
agents and the development of predictive biomarkers of response.
The Akt inhibitor, GSK690693 was reported to have modest anti-
tumor activity in the PPTP testing as intermediate activity against
two of six OS xenografts was demonstrated (Carol et al., 2010b).
One planned study to investigate GSK690693 in pediatric subjects
with relapsed or refractory hematologic malignancies was with-
drawn prior to patient enrollment and this agent has not been
clinically studied for any pediatric malignancies.
MEK1/2 INHIBITOR
MAPK or extracellular receptor kinase (ERK) is activated by
MAPK/ERK kinase (MEK). MEK1 and MEK2 are dual-specificity
protein kinases that function in the MAPK signaling cascade to
control cell growth and differentiation (Bromberg-White et al.,
2012). MEK1/2 is stimulated by a wide variety of growth factors
and cytokines and also by membrane depolarization and calcium
influx. Ras/Raf is upstream of MEK and aberrant activation of
the Ras/Raf/MEK/MAP kinase pathway (MAPK pathway) is asso-
ciated with the pathogenesis of many cancers including OS lung
metastasis (Yu et al., 2011). Many growth factor receptors associ-
ated with the biology of OS (IGF-1R, EGFR, VEGFR, and PDGFR)
activate the MAPK/ERK pathway to make it a powerful target
for therapeutic intervention. AZD6244 is a potent and specific
inhibitor for MEK 1/2 and demonstrated effective tumor growth
inhibition in the PPTP OS panel. AZD6244 demonstrated inter-
mediate activity in three of six OS xenograft lines (Kolb et al.,
2010). This compound is also in development for pediatric glioma
through the Pediatric Brain Tumor Consortium (PBTC) and is
currently in phase II testing of pediatric patients with melanoma
but has not yet entered the pipeline for clinical development for
pediatric sarcomas. There are other MEK inhibitors including
trametinib (GlaxoSmithKline) and pimasertib (MERK) in clinical
development for patients with melanoma.
CYCLIN-DEPENDENT KINASE INHIBITOR
Cyclin-dependent kinases regulate orderly progression through
the cell cycle. Activated by association with cyclins, Cdks phos-
phorylate key regulatory substrates such as the Rb protein (Stone
et al., 2012). CDKs are frequently upregulated in human can-
cers along with overexpression of cyclin partners or inactivation
of CDK inhibitors. Inhibitors of CDKs such as seliciclib and
alvocidib induce the apoptosis of several tumor cells. Dinaci-
clib (SCH 727965) is capable of specific inhibition of CDKs with
low nanomolar potency against CDK1, CDK2, CDK5, and CDK9
and induces cell cycle arrest and apoptosis (Parry et al., 2010).
Interest in CDKs as a therapeutic target stems from the cen-
tral role in cell cycle regulation, the modest toxicity of this class
of chemotherapy, activity against CLL and the existing preclini-
cal data in adult histotypes (Gorlick et al., 2012b). When tested
against the PPTP OS panels, stable disease was observed in one
xenograft. A separate study has shown that dinaciclib-induced
apoptosis of several OS cell lines was p53-independent (Fu et al.,
2011). Dinaciclib is not currently in clinical development for
pediatric malignancies but these findings support further preclin-
ical testing of this novel small-molecule multi-CDK inhibitor in
combination therapies to enhance the anti-tumor activity in OS
cells.
p53 INHIBITOR
The transcription factor and tumor suppressor p53 is activated
in cells in response to DNA damage. MDM2 (mouse double
minute 2) binds and inactivates p53 to promote ubiquitination and
proteasomal degradation for the p53 growth-suppressive func-
tion in unstressed cells. Selective inhibitors have been developed
which disrupt binding of p53 and MDM2, to activate the p53
pathway in cancer cells leading to cell cycle arrest and apopto-
sis. Mutations in p53 (Miller et al., 1990) and amplification of
MDM2 have been reported in OS, though with relatively low inci-
dence in comparison to adult malignancies (Mejia-Guerrero et al.,
2010). Serdemetan (JNJ-26854165) was originally developed as an
MDM2 antagonist that activates the p53 protein to induce apopto-
sis in cancer cell lines. In the PPTP testing, this agent demonstrated
tumor growth inhibition in the OS models (Smith et al., 2012a).
An objective response was observed in one xenograft in the OS
panel (MCR) and intermediate activity (PD2) was observed in
another tumor. In a separate study, OS cells that express wild type
p53 were sensitive to nutlin-3 which also targets the p53-MDM2
axis (Wang et al., 2012). A phase I clinical trial for serdemetan in
adults with advanced solid tumors reported no objective responses
and prolonged SD in three patients (Tabernero et al., 2011). This
agent has not been studied in pediatric OS, but future testing
of MDM2 antagonists for the treatment of this disease can be
explored. Additionally, since Akt also activates MDM2 and inhibits
p53, combination strategies with Akt inhibitors may have additive
benefits in OS.
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CENTROMERE-ASSOCIATED PROTEIN E INHIBITOR
The centromere kinesin motor protein (CENP-E) is a recent can-
didate for molecular targeting in cancer. CENP-E is required for
correct chromosomal alignment in mitosis. This protein integrates
mitotic spindle mechanics with mitotic checkpoint signaling and
is overexpressed in a variety of human tumors suggesting a role
in tumor cell proliferation. Inhibition of CENP-E in cultured
human tumor cells leads to cell cycle arrest in mitosis with bipolar
mitotic spindles and misaligned chromosomes and eventual cell
death. In the PPTP testing of GSK923295A, two OS xenografts
met the criteria for high activity with a CR or MCR (Lock et al.,
2012). These results demonstrate that CENP-E may be a valu-
able target in OS and suggest further in vivo evaluation in the
context of tolerable doses achievable in humans. GSK923295A is
currently in a phase I clinical trial for adults with solid tumors
however this agent is not in clinical development for pediatric OS
patients.
HISTONE DEACETYLASE INHIBITOR
Histone deacetylases (HDACs) regulate acetylation of histone
lysine residues which triggers transcriptional activity promoting
cell transformation and proliferation. Deregulation of histone
acetylation is associated with disease pathogenesis by promot-
ing alterations in chromatin structure and gene transcription.
HDAC inhibitors induce growth arrest and cell death by epi-
genetic changes in many preclinical and clinical cancer mod-
els. Vorinostat is an oral HDAC inhibitor of class I and II
HDACs that is in clinical trials for hematologic and solid tumors
that metastasize and compromise bone structure. Vorinostat is
approved for cutaneous T-cell lymphoma and has advanced
to phase III clinical trials for multiple myeloma. It is also in
many phase II trials including acute myeloid leukemia, B-cell
lymphoma, glioblastoma, myelodysplastic syndromes, and breast
cancer.
Preclinical studies of vorinostat in the PPTP revealed inter-
mediate activity (PD2) in two of four OS tumors (Keshelava
et al., 2009). Vorinostat has been tested in combination with
13-cis retinoic acid (13cRA) in a COG study in children with
refractory solid tumors (Fouladi et al., 2010) and in preclin-
ical medulloblastoma models (Spiller et al., 2008). A phase I
clinical trial testing vorinostat with and without isotretinoin
(NCT00217412), and another COG trial testing vorinostat in com-
bination with bortezomib in children with refractory or recurrent
solid tumors (NCT01132911) (Muscal et al., 2013) were recently
concluded. In these studies, only a moderate effect of vorinostat
was observed and treatment of metastatic tumors with vorinos-
tat had limited success. Current phase II studies enrolling pedi-
atric OS patients include the testing of vorinostat in children
(NCT01422499) and in combination with etoposide in pediatric
patients younger than 21 years at diagnosis with refractory solid
tumors (NCT01294670). A role for HDACs in deregulating Notch
pathway expression was shown to contribute to the ability of
OS cells to metastasize in one study. A better understanding of
the effects of HDAC inhibitors in combination with epigenetic
and DNA damaging drugs may be essential in planning therapies
with vorinostat and other signal-transduction pathway inhibitors
in OS.
SECOND MITOCHONDRIA-DERIVED ACTIVATOR OF CASPASES
The elucidation of the structure and function of the second
mitochondria-derived activator of caspases (Smac) protein has
triggered the development of Smac derivatives and mimetics for
use in cancer treatment. During programed cell death, Smac, an
endogenous proapoptotic protein of the mitochondria is released
and promotes apoptosis via inhibition or proteasomal degradation
of the inhibitor of apoptosis (IAP) family of proteins. Included in
the IAP family is X-linked IAP protein (XIAP) and cellular-linked
IAP protein-1 and -2 (cIAP1 and cIAP2) (Chen and Huerta, 2009).
Smac mimetics induce the auto-ubiquitylation and proteasomal
degradation of cIAP1 and cIAP2 to increase nuclear factor κB
(NF-κB) signaling and tumor necrosis factor-α (TNFα) produc-
tion leading to caspase-8 activation and apoptosis. Overexpression
of Smac has been shown to sensitize OS cells in vitro to chemother-
apeutic drug-induced apoptosis (Hotta et al., 2003). Thus, the use
of small-molecule drugs that act as Smac mimetics in OS cells that
overexpress IAPs or underexpress Smac might be a potent strategy
to elicit a proapoptotic anti-cancer response.
LCL161 is a small-molecule Smac mimetic which induces apop-
tosis in some cancer cell lines and potentiates the effects of tyrosine
kinase inhibition (Houghton et al., 2012b). LCL161 demonstrated
tumor growth delay in five of six OS xenografts and intermediate
activity in one xenograft in the PPTP. A phase I,multi-center,open-
label, dose-escalation study of oral LCL161 in adult patients with
advanced solid tumors was recently completed (NCT01098838).
A phase I study of safety and efficacy in combination with pacli-
taxel in with advanced solid tumors is ongoing. LCL161 has not
been studied in pediatric patients with OS. The future application
of small-molecule Smac mimetics as a treatment for OS warrants
further investigation in multi-agent therapies with chemotherapy
or other targeted therapies inclusive of agents that target apoptosis.
TARGETING DNA AND MITOSIS
In a tumor marked by aneuploidy, targeting the mitotic spin-
dle and DNA repair are considered to be reasonable therapeutic
approaches. While typically considered non-targeted or conven-
tional chemotherapies, mitotic spindle poisons and topoisomerase
inhibitors are included in this review. Vincristine was highly active
against one OS xenograft (Houghton et al., 2007), while eribulin,
a novel, fully synthetic compound capable of irreversible mitotic
blockade showed high and intermediate activity against five of six
OS xenografts in the PPTP (Kolb et al., 2013). Eribulin is cur-
rently approved for the treatment of recurrent metastatic breast
cancer.
Topoisomerases maintain the helical structure of DNA. Two
topoisomerase inhibitors topotecan a small-molecule DNA topoi-
somerase I poison (Anderson et al., 2008) and Genz-644282, a
novel non-camptothecin topoisomerase I inhibitor that is already
in clinical development for adult malignancies, were tested by the
PPTP. Topotecan achieved intermediate activities (PD2) in all six
OS xenografts (Carol et al., 2010a). A phase I study by COG eval-
uated topotecan administered by 21-day continuous infusion of
topotecan in children with relapsed or refractory solid tumors.
Of the 11 OS patients enrolled, one demonstrated SD and nine
had PD (Hawkins et al., 2006). The development of topotecan in
multi-agent therapy is suggested. Following treatment with the
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Genz-644282 inhibitor, four of five OS xenografts showed objec-
tive responses and the fifth showed PD2 (Houghton et al., 2012c)
in PPTP testing. A phase I dose-escalation study to assess the safety
and tolerability of Genz-644282 in adult patients with solid tumors
is in progress but pediatric patients are not enlisted.
THE PROGRESSIVE SEARCH FOR TARGETED THERAPIES IN
OSTEOSARCOMA
The identification of new therapeutic drugs using strategies which
target cell proliferation (multi-tyrosine kinase receptor inhibitors),
angiogenesis (VEGF inhibitors), apoptosis, and DNA cytotoxicity
in combination with standard chemotherapy has demonstrated
promise in preclinical and early-phase clinical trials for OS. Signif-
icantly, these studies also highlight many of the major challenges
faced by clinicians and researchers in the development of novel
drugs and therapies for this disease. Many signal-transduction
pathways activated by binding of growth factors to their receptors
are proven “druggable” targets. However, the responses are vari-
able and the most dramatic benefits seen with biologic agents in
ongoing studies are in the adjuvant setting. It is now apparent that
successful treatment for this heterogeneous disease will involve
combination strategies of new agents or personalized therapies.
This integrated approach is anticipated to help realize the true
potential of targeted therapies in OS.
The emergence of numerous anti-cancer agents and the small
number of OS patients eligible for early-phase clinical trials
present another challenge in the clinical testing of novel com-
pounds. Predictive animal model systems for preclinical studies of
safety assessment, drug metabolism, and pharmacokinetics may
help to inform and prioritize available drugs for clinical devel-
opment. The systematic preclinical evaluation of new agents in
pediatric cancer has received tremendous support by the efforts
of the NCI-supported PPTP (Houghton et al., 2007). Since 2007,
this program has facilitated the comprehensive analysis of more
than 50 novel and standard agents in in vitro and in vivo panels of
childhood cancers.
The PPTP has demonstrated that OS xenografts provide a
rapid and efficient platform for the testing of new therapies for
anti-tumor effects. Given the complex genomic changes that are
associated with this disease, validation of xenografts is necessary
to ensure the use of robust OS model systems and to reduce dis-
crepancies and errors in molecular studies and drug screening.
Gene expression profiling of the in vitro and in vivo OS panels
of the PPTP has shown that gene expression patterns are pre-
served in OS cell lines and xenografts (Houghton et al., 2007).
Consequently, the activity of an agent in these preclinical mod-
els of OS is considered controllable, reproducible, and potentially
informative of clinical activity in patients. However, there are
notable exceptions to these expectations. The PD results of the
phase II study of continuous-infusion topotecan (Hawkins et al.,
2006) did not reflect the favorable response reported in the PPTP
testing (intermediate activity) (Carol et al., 2010a). Different dos-
ing schedules and pharmacokinetics in mice and humans and the
interpretation of data may result in false positive and false neg-
ative xenograft results. Nonetheless, OS xenograft models offer a
link between preclinical and clinical testing with the potential of
benefits to pediatric patients.
The PPTP is testing the hypothesis that OS xenografts can pre-
dict activity in clinical testing for some OS patients (Table 1).
Phase I and II clinical trial results for cixutumumab, sorafenib,
and rapamycin have demonstrated that these preclinical mod-
eling systems are effective (Chawla et al., 2012; Grignani et al.,
2012; Malempati et al., 2012) as these agents with high levels of
response in the PPTP are well-tolerated and demonstrated promis-
ing anti-tumor activity in some adult and pediatric patients.
Importantly also, the PPTP has tested several agents with high
clinical successes in the treatment of other malignancies which do
not yield similar responses in OS (summarized in Table 2). These
include the inhibitor lapatinib which has clinical efficacy against
ErbB2-overexpressing breast cancer but showed little single-agent
activity against the xenografts of the PPTP in vivo panel (Gorlick
et al., 2009). Further, in contrast to serdemetan, the p53-MDM2
inhibitor RG7112 (Carol et al., 2013) did not show significant
tumor regression in the PPTP OS tumors highlighting the dif-
ferences in potencies and toxicities of similarly targeted drugs
(Table 2). Insufficient proof of target inhibition in preclinical
testing may also suggest limited clinical benefits of such agents.
Establishing these critical elements of efficacy and toxicity is
expected to avert the clinical testing of ineffective agents and
assist in the prioritization of agents for OS drug discovery and
development.
The screening of multiple patient-derived OS xenografts gen-
erated from different cell lines in the PPTP panels also leverages
the molecular diversity in OS to provide comparative screening
for improved drug evaluation. The MCR and PD2 responses in
the in vivo OS xenografts following anti-IGF-1R targeted ther-
apy (Kolb et al., 2008b) demonstrate clear heterogenous responses
in these tumors. These preclinical responses are significant since
variable responses were also observed in early-phase clinical tri-
als using the fully humanized mAbs SCH 717454, cixutumumab,
and R1507 (Wang et al., 2010; Pappo et al., 2011; Malempati
et al., 2012). The PPTP panels therefore provide a framework
for evaluating models of mechanisms of action and mechanisms
of resistance for individual agents. Further preclinical experi-
ments which focus on activation of oncogenic signaling pathways
that maintain aberrant cell proliferation can be studied in these
tumors. Evidence of acquired resistance through activation of
the PI3K/Akt pathway has been described in the evaluation of
sorafenib, IGF-1R, and mTOR inhibitors as monotherapy in the
preclinical setting (Juergens et al., 2011; Quek et al., 2011; Pig-
nochino et al., 2013). Other resistance mechanisms may not be
specific to an inhibitor, but rather reflect a compensatory response
to toxic stimuli. Preclinical studies of mechanism and response
would aid in framing decisions when translating these targeted
therapies to the clinic.
By design, some preclinical testing strategies present inherent
limitations. Almost all mAbs in clinical trials are either chimeric
or humanized antibodies produced in transgenic mice. Thus the
fully human monoclonal anti-GD2 antibody (ch14.18) which tar-
gets the ganglioside GD2, that is expressed on the surface of OS
and Ewing sarcoma cells and denosumab which binds and neutral-
izes the activity of the receptor activator of nuclear factor kappa B
ligand (RANK-L) cannot be tested in mice. Canine models reca-
pitulate the primary human disease and provide a useful platform
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for the development of more effective treatments for both humans
and canines. Spontaneous OS is the most common primary bone
tumor in dogs with many phenotypic and molecular similarities
between dogs and humans (Mueller et al., 2007). Of note, the
majority of in vivo OS models have addressed the conventional,
high-grade types of OS which are the most frequently occurring
subtypes of this disease. Rarer subtypes which include low-grade,
small cell, telangiectatic, periosteal, and high-grade surface OS
which present with distinguishing genetic features may have dif-
ferent drug responses to conventional tumors (Martin et al., 2012).
The use of preclinical models for the identification of accurate bio-
markers of response and resistance that correlate changes of the
molecular target to the drug treatment will serve as key elements
in the successful translation of preclinical results to the clinical
setting.
In summary, the goal to find new targeted therapies for
patients with OS has seen the development of suitable in vivo
models and advanced testing strategies for the evaluation of
different targets and therapies. A wealth of preclinical and clin-
ical data of agents with activity in OS now exists which pro-
vides support for novel, single-agent therapies currently in clinical
development. Future work evaluating these agents in the pre-
clinical models can focus on their utility in novel, multi-agent
combinations, to justify future approaches that may result in
improved prognosis of pediatric patients. The search for new
treatment strategies is ongoing and there remains considerable
hope that progressive and continuous research through these
preclinical testing programs will fully exploit the potential of tar-
geted therapies in OS to maximize the benefits in this pediatric
disease.
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